Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Endocr Relat Cancer. 2018 Feb;25(2):T91–T104. doi: 10.1530/ERC-17-0411

Figure 4.

Figure 4

A. Vandetanib suppressed RET-mediated transformation of eye epithelia. B. AD80 acts through altered networks. C. Genetic identification of sorafenib’s pro/anti-target network led to the TCI lead APS6-45, which showed favorable mouse activity. Adapted from Read et al, 2005, Dar et al, 2012, Sonoshita et al, in press.